Alto Neuroscience, Inc. (NYSE:ANRO) Receives $24.40 Average PT from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $24.40.

A number of equities analysts have recently commented on the stock. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Finally, Robert W. Baird dropped their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently added to or reduced their stakes in ANRO. RA Capital Management L.P. bought a new position in Alto Neuroscience during the 1st quarter worth $21,267,000. Price T Rowe Associates Inc. MD bought a new position in shares of Alto Neuroscience in the first quarter worth $9,788,000. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience in the first quarter worth $8,233,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience in the first quarter worth $7,039,000. Finally, Artal Group S.A. bought a new position in shares of Alto Neuroscience in the first quarter worth $5,372,000.

Alto Neuroscience Stock Up 0.7 %

NYSE ANRO opened at $4.04 on Thursday. The company’s fifty day moving average price is $11.64 and its two-hundred day moving average price is $12.13. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a 12 month low of $3.90 and a 12 month high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.07. Equities analysts anticipate that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.